Formycon Reports Positive Phase III Data On Ustekinumab
Company Is Looking For Marketing Partner On Stelara Biosimilar By Year End
• By David Wallace
Formycon has celebrated the latest results for its FYB202 ustekinumab candidate • Source: Shutterstock 
